Ashvattha’s new self-administered anti-VEGF therapy may address unmet needs for DME
Ashvattha Therapeutics’ D-4517.2 stands out among anti-VEGF treatments in that it can be self-administered using an autoinjector.
By
Ashvattha Therapeutics’ D-4517.2 stands out among anti-VEGF treatments in that it can be self-administered using an autoinjector.
ByFurther trials for pediatric and heart failure patients are currently ongoing.
ByWith the latest development, the new treatment will benefit nearly 425,000 individuals.
The approval is based on findings from Phase III EXPLORER-HCM clinical trial that enrolled 251 adults with obstructive HCM.
The antibodies showed potential for treating individuals who are at high-risk for atherosclerotic cardiovascular disease.
The additional clinical benefits empagliflozin offers will strengthen its position in an increasingly competitive SGLT-2I class.
ByMavacamten is a selective cardiac myosin inhibitor currently in pre-registration for hypertrophic cardiomyopathy (HCM) in the US.
ByThe EC approval is based on results from the Phase III EMPEROR-Preserved trial of 10mg empagliflozin versus placebo.
Thank you for subscribing to Pharmaceutical Technology